Topic
How are GLP-1s changing American life?
Sourced stories on how GLP-1s are reshaping food, celebrity, work and the American economy.
Celebrities on Mounjaro and Zepbound: Who Said WhatFour public figures have named Mounjaro or Zepbound themselves: Shaquille O'Neal with Zepbound, and Whoopi Goldberg, Sunny Hostin and Tori Spelling with Mounjaro. Serena Williams disclosed GLP-1 treatment without naming a brand, and several disclosures are paid corporate campaign partnerships.Celebrities on Ozempic: Who Actually Said They Take ItOprah, Elon Musk, Serena Williams, Whoopi Goldberg and others have publicly confirmed taking a weight-loss drug — but only some are actually on Ozempic. Here is what each one said, which drug they named, and which disclosures are commercial partnerships.How Eli Lilly's GLP-1 Boom Reshaped the Indianapolis EconomyLilly's Indiana operations generate nearly $20.7 billion in state GDP — 3.6% of Indiana's total — and support an estimated 46,600 jobs, per an IU Kelley School study, with more than $21 billion in new Indiana investment since 2020.How Many Americans Take GLP-1 Drugs? The Latest NumbersKFF found 12% of US adults currently taking a GLP-1 for any reason (survey fielded October 27–November 2, 2025). Gallup found 11% currently taking one for weight loss only (fielded May 28–June 5, 2026); ever-use is 15% per Gallup and 18% per KFF.How Many Americans Take Zepbound? What the Published Numbers ShowNo official count of US Zepbound users has been published. What exists is Lilly's audited revenue: Zepbound made $13,542 million in 2025, up 175%, and Lilly says it was the most prescribed weight management medication that year.How Ozempic Changed American Culture: From Slang to Everyday LifeGLP-1 drugs moved from diabetes clinics to the Oscars stage, slang dictionaries and plastic surgeons' offices: 67% of facial plastic surgeons surveyed in December 2025 reported more patients seeking treatment for rapid-weight-loss changes.How Zepbound Overtook Wegovy in the US Weight-Loss MarketZepbound first beat Wegovy on new US prescriptions the week ending March 8, 2024, and by March 2026 Lilly held 60.1% of the US incretin market. Here is the timeline, the trial data, and the pricing moves behind the shift.Ozempic and Eating Disorders: What's Known and What Isn'tNo research shows that Ozempic or other GLP-1 drugs cause eating disorders. But 60–70% of users lose significant, sometimes rapid weight, which NEDA flags as a specific concern for anyone with a current, past, or high-risk eating disorder. Here's what the evidence does and doesn't say.The GLP-1 Economy: Who Wins and Loses as Weight-Loss Drugs SpreadDrug makers, protein foods, and apparel win so far; snacks, sweets, soft drinks, and quick-service restaurants lose the most. Households starting a GLP-1 cut grocery spending 5.3% on average within six months, and the drug market is forecast to grow from $79 billion in 2025 to $190 billion by 2035.